Company Presentation Feb 28, 2023 Company Presentation Other Presentations November 11, 2022 The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity November 11, 2022 The Epi-R technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function November 11, 2022 Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform November 11, 2022 Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology November 10, 2022 NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo September 12, 2022 ESMO: Phase 1 Study of LYL797, a ROR1-Targeted CAR T-Cell Therapy With Genetic and Epigenetic Reprogramming for the Treatment of Advanced Solid Tumors June 17, 2022 ISSCR: T-Cell Rejuvenation: A Novel Approach for Partially Reprogramming T Cells to Improve Their Immunotherapeutic Properties May 18, 2022 ASGCT: Epigenetic reprogramming (Epi-R™) yields an NY-ESO-1 T-cell receptor product (LYL132; GSK4427296) with improved stemness, metabolic fitness, and functional activity in the presence of persistent antigen exposure May 16, 2022 ASGCT: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors April 8, 2022 AACR 2022: LYL797, a ROR1 CAR T-Cell Therapy With Genetic and Epigenetic Reprogramming for Solid Tumors
